Invesaro

Stocks Comparison

Immucell vs Idexx Laboratories: revenue, profit, margins and growth compared

Immucell brought in $27.6M of revenue in fiscal 2025, Idexx Laboratories $4.3B in fiscal 2025. Revenue changed by +4.3% at Immucell and +10.4% at Idexx Laboratories on the year before, so Idexx Laboratories grew faster. Immucell kept -3.8% of its revenue as net profit, Idexx Laboratories 24.6%. Free cash flow was $1.2M at Immucell and $1.1B at Idexx Laboratories.

Side by side, latest fiscal year

ICCCIDXX
Fiscal year endedFY2025 (December 31, 2025)FY2025 (December 31, 2025)
Revenue$27.6M$4.3B
Revenue growth+4.3%+10.4%
Net income-$1M$1.1B
Net margin-3.8%24.6%
Free cash flow$1.2M$1.1B
Free cash flow margin4.4%24.6%
Earnings per share (diluted)-$0.12$13.08
Cash$3.8M$180.1M
Debt$9.1M$450M
Price to earningsn/a39.7
Market value$90.1M$40.9B
Dividend yieldn/an/a
Rank by revenue in sector#396 of 523 · Health care#67 of 523 · Health care

Over the years

Revenue
ICCC FY2018: $11MICCC FY2019: $13.7MICCC FY2020: $15.3MICCC FY2021: $19.2MICCC FY2022: $18.6MICCC FY2023: $17.5MICCC FY2024: $26.5MICCC FY2025: $27.6MIDXX FY2018: $2.2BIDXX FY2019: $2.4BIDXX FY2020: $2.7BIDXX FY2021: $3.2BIDXX FY2022: $3.4BIDXX FY2023: $3.7BIDXX FY2024: $3.9BIDXX FY2025: $4.3BFY18FY19FY20FY21FY22FY23FY24FY25
ICCC $27.6MIDXX $4.3B
Net income
ICCC FY2018: -$2.3MICCC FY2019: -$1.3MICCC FY2020: -$1MICCC FY2021: -$78.3KICCC FY2022: -$2.5MICCC FY2023: -$5.8MICCC FY2024: -$2.2MICCC FY2025: -$1MIDXX FY2018: $377MIDXX FY2019: $427.7MIDXX FY2020: $581.8MIDXX FY2021: $744.8MIDXX FY2022: $679.1MIDXX FY2023: $845MIDXX FY2024: $887.9MIDXX FY2025: $1.1BFY18FY19FY20FY21FY22FY23FY24FY25
ICCC -$1MIDXX $1.1B
Net margin
ICCC FY2018: -21.1%ICCC FY2019: -9.4%ICCC FY2020: -6.7%ICCC FY2021: -0.4%ICCC FY2022: -13.4%ICCC FY2023: -33.1%ICCC FY2024: -8.1%ICCC FY2025: -3.8%IDXX FY2018: 17.0%IDXX FY2019: 17.8%IDXX FY2020: 21.5%IDXX FY2021: 23.2%IDXX FY2022: 20.2%IDXX FY2023: 23.1%IDXX FY2024: 22.8%IDXX FY2025: 24.6%FY18FY19FY20FY21FY22FY23FY24FY25
ICCC -3.8%IDXX 24.6%
Revenue growth
ICCC FY2019: +24.9%ICCC FY2020: +11.8%ICCC FY2021: +25.4%ICCC FY2022: -3.5%ICCC FY2023: -5.9%ICCC FY2024: +51.6%ICCC FY2025: +4.3%IDXX FY2019: +8.8%IDXX FY2020: +12.5%IDXX FY2021: +18.8%IDXX FY2022: +4.7%IDXX FY2023: +8.7%IDXX FY2024: +6.5%IDXX FY2025: +10.4%FY19FY20FY21FY22FY23FY24FY25
ICCC +4.3%IDXX +10.4%
Free cash flow
ICCC FY2018: -$2.4MICCC FY2019: -$1.2MICCC FY2020: -$2.8MICCC FY2021: -$1.7MICCC FY2022: -$5.5MICCC FY2023: -$6.6MICCC FY2024: -$107.8KICCC FY2025: $1.2MIDXX FY2018: $284.3MIDXX FY2019: $304.2MIDXX FY2020: $541.1MIDXX FY2021: $636MIDXX FY2022: $394.1MIDXX FY2023: $772.9MIDXX FY2024: $808.1MIDXX FY2025: $1.1BFY18FY19FY20FY21FY22FY23FY24FY25
ICCC $1.2MIDXX $1.1B

Fiscal years as each company reports them; the two may end in different months.

Questions about Immucell and Idexx Laboratories

Which is bigger by revenue, Immucell or Idexx Laboratories?

Idexx Laboratories is bigger by revenue: $4.3B in fiscal 2025, against $27.6M for Immucell in fiscal 2025.

Which keeps more of its revenue as profit, Immucell or Idexx Laboratories?

Immucell had a net margin of -3.8% in fiscal 2025; Idexx Laboratories had 24.6% in fiscal 2025.

Which grew revenue faster, Immucell or Idexx Laboratories?

In their latest fiscal years revenue changed by +4.3% at Immucell and +10.4% at Idexx Laboratories.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies